ssCART-19

Phase 2Cell therapy

SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

ssCART-19 is one of 59 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

ssCART-19

SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Phase 2

2 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Lymphoma

NCT07093073

Q2 2030

Phase 1/2Recruiting

Lymphoma

NCT06987916

Clinical

Trials by Indication[1]

Lymphoma2 trials

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

Recruiting·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1/2·NCT06987916·50 enrolled

Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

Recruiting·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1·NCT07093073·30 enrolled

Acute Lymphoblastic Leukemia1 trial

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Not yet recruiting·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 2·NCT06367114·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ssCART-19. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ssCART-19 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ssCART-19. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

ssCART-19

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q2 2030

Trials by Indication[1]

Lymphoma2 trials

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News